GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Tangible Book per Share

Monopar Therapeutics (Monopar Therapeutics) Tangible Book per Share : $0.43 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Monopar Therapeutics's tangible book value per share for the quarter that ended in Mar. 2024 was $0.43.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Monopar Therapeutics Tangible Book per Share Historical Data

The historical data trend for Monopar Therapeutics's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monopar Therapeutics Tangible Book per Share Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial 1.19 1.37 1.50 0.78 0.38

Monopar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.56 0.47 0.38 0.43

Competitive Comparison of Monopar Therapeutics's Tangible Book per Share

For the Biotechnology subindustry, Monopar Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monopar Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Monopar Therapeutics's Price-to-Tangible-Book falls into.



Monopar Therapeutics Tangible Book per Share Calculation

Monopar Therapeutics's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(5.588-0-0)/14.9045
=0.37

Monopar Therapeutics's Tangible Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(7.477-0-0)/17.4842
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Monopar Therapeutics  (NAS:MNPR) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Monopar Therapeutics Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Monopar Therapeutics (Monopar Therapeutics) Business Description

Traded in Other Exchanges
Address
1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Executives
Michael J Brown director C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner director ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson director C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto officer: Chief Financial Officer C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson director, officer: Chief Executive Officer C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Andrew Cittadine officer: Chief Operating Officer C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Patrice Rioux other: Acting Chief Medical Officer C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr director C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa officer: Chief Medical Officer C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc 10 percent owner C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks 10 percent owner C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo 10 percent owner C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson officer: SVP, Clinical Development C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc 10 percent owner C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc 10 percent owner 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091

Monopar Therapeutics (Monopar Therapeutics) Headlines